← All trials
NCT01586260
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2012
- Primary completion
- Jun 1, 2018
- Completion date
- Jun 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 89
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- The Spectrum Health GroupLead sponsor
- Cancer Prevention Pharmaceuticals, Inc.Collaborator
- University of ArizonaCollaborator
- University of HawaiiCollaborator
- University of VermontCollaborator
- The Spectrum Health GroupSponsor investigator
- The Spectrum Health GroupStudy chair
- Beat NB Cancer FoundationCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.